Lyra Therapeutics, Inc. announced that new LYR-210 data analyses from the Phase 2 LANTERN study will be presented at the 68th Annual Meeting of the American Rhinologic Society (ARS) in Philadelphia. The additional results from the previously-reported Phase 2 LANTERN study showed that LYR-210 (7500µg) significantly improved symptom severity from baseline of 3 cardinal symptoms (3CS) of chronic rhinosinusitis (CRS) – nasal blockage, nasal discharge, and facial pain/pressure – when assessed in a responder analysis as individual and composite symptom scores at week 24. Compared to control, significantly higher proportions of LYR-210-treated subjects improved from moderate or severe at baseline to mild or none at week 24 in nasal blockage, nasal discharge, and facial pain/pressure (p<0.05).

Consistent with other reported data from the LANTERN study, LYR-210 demonstrated a dose-dependent response in the 3CS severity analysis. A second oral presentation for LYR-210 at the ARS meeting will highlight the correlation between the 3CS composite scores and Sino-Nasal Outcome Test (SNOT-22) scores. The data show that the clinical changes in CRS patients measured in the 3CS composite score strongly and significantly correlate with the change in SNOT-22 total score, based on data evaluated at week 24 in the LANTERN study.

Both assessments, 3CS and SNOT-22, provide critical information on a patient's response to treatment and the impact CRS has on quality of life.